1. Arquitos Capital Management reported strong returns of 29.6% net in Q2 2025, with a year-to-date return of 66.8%, driven by a focus on undervalued small-cap companies and long-term holdings. 2. Key holdings like Liquidia and Finch Therapeutics showed significant progress, including FDA approvals, litigation wins, and commercial success, while ENDI Corp demonstrated growth in assets and undervaluation. 3. The fund emphasizes patience, absolute returns, and comparisons to the Russell 2000 Small Cap Index, anticipating small-cap outperformance in the coming decade.